F2G will present six posters in ‘Poster session 105: New Antifungal Agents’ and the Company’s CSO, Dr Lloyd Payne, has also been allocated a speaking slot during the Saturday morning Poster Summary Session 3 entitled ‘All New Antimicrobial Agents’. Shane Kelly, Chief Executive of F2G, commented “We are delighted that the ICAAC Organising Committee has accepted our poster presentations and invited us to speak at the conference. This invitation represents an important validation of our science and is a significant achievement for the company. 2008 has been a milestone year as our candidate drug, which originates from F2G’s in-house screening program, has entered full preclinical development.”
F2G’s candidate drug represents the first generation of a novel class of systemic antifungal agent and offers the potential for a major advance in antifungal therapy. The mechanism of action, identified by scientists at F2G, involves the selective inhibition of a fungal enzyme and is completely distinct from any other class of marketed antifungal agent. The compound displays highly potent activity against a wide range of clinically significant moulds including the common pathogen Aspergillus fumigatus which is known to cause Invasive Aspergillosis, a serious, debilitating disease associated with high mortality rates despite current therapy options.
The planned poster presentations at ICAAC 2008 highlight the potent in vitro antifungal activity of the new compound against a wide range of clinically significant fungi including Aspergilli sp. The pharmacokinetics profile of the agent and its ADMET properties are described as well as data pertaining to the excellent efficacy of the novel agent in highly validated models of Aspergillus infection.
About F2G Ltd:
Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over five and a half billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma.
F2G recently completed a ?6.3million equity financing round with an international syndicate of investors to fund the further development of the company’s lead compound and back-up programs. The company has impressive internal capabilities, employing a core team of scientists with a unique understanding of the antifungal arena, supported by an experienced management team. F2G operates a flexible business model, building value through the development of a balanced portfolio of antifungal assets across multiple validated TPPs.
